Please assess the completion status of the following clinical trial:

Trial Title: Long-term Daily Use of Trazenta® Tablets in Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Male and female patients with type 2 Diabetes Mellitus who have never been treated with Trazenta tablets / Linagliptin (monotherapy) before enrollment. (Trazenta group)~* Patients with type 2 Diabetes Mellitus starting any other oral antidiabetic monotherapy (naïve or switched from prior therapy of different oral antidiabetic drug (OAD)) except Trazenta tablets. (OAD group)~Exclusion criteria:~None

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Oral antidiabetic drug (OAD) (Type: None): None
- Trazenta (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).